Q1WB
CRL icon

Quest 10 Wealth Builders’s Charles River Laboratories CRL Stock Holding History

Quest 10 Wealth Builders’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$253 – 787
2025
Q4 		$253 Hold
1
– – ﹤0.01% 742
2025
Q3 		$199 Hold
1
– – ﹤0.01% 843
2025
Q2 		$193 Hold
1
– – ﹤0.01% 753
2025
Q1 		$191 Buy
+1
New +$168 ﹤0.01% 735

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Quest 10 Wealth Builders's CRL Position: Q1 2026 in Review

Quest 10 Wealth Builders sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 1 share — an estimated $253 sold.

Quest 10 Wealth Builders first reported a position in CRL in Q1 2025 and held it in 4 quarters. The position peaked at $253 in Q4 2025. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Quest 10 Wealth Builders reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Quest 10 Wealth Builders sold 1 Charles River Laboratories share in Q1 2026, an estimated $253.
  • Quest 10 Wealth Builders first reported a position in Charles River Laboratories in Q1 2025 and held it in 4 quarters.
  • Quest 10 Wealth Builders's Charles River Laboratories position peaked at $253 in Q4 2025.
  • 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Quest 10 Wealth Builders's 13F filing for Q1 2026, filed 6 May 2026.